MC3138
| Clinical data | |
|---|---|
| Drug class | Sirtuin-5 (SIRT5) activator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H25NO6 |
| Molar mass | 435.476 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MC3138 is a drug which acts as a sirtuin-5 (SIRT5) activator. It has potential applications in the treatment of pancreatic cancer, as well as basic research into the function of the SIRT5 enzyme complex.[1][2][3]
References
- ^ Hu T, Shukla SK, Vernucci E, He C, Wang D, King RJ, et al. (November 2021). "Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression". Gastroenterology. 161 (5): 1584–1600. doi:10.1053/j.gastro.2021.06.045. PMC 8546779. PMID 34245764.
- ^ Barreca F, Aventaggiato M, Vitiello L, Sansone L, Russo MA, Mai A, et al. (August 2023). "SIRT5 Activation and Inorganic Phosphate Binding Reduce Cancer Cell Vitality by Modulating Autophagy/Mitophagy and ROS". Antioxidants. 12 (8): 1635. doi:10.3390/antiox12081635. PMC 10451763. PMID 37627630.
- ^ Liu XW, Huang SS, Xu P, Xu HW, Wang DK, Wang SJ (April 2025). "Transcription factor EP300 targets SIRT5 to promote autophagy of nucleus pulposus cells and attenuate intervertebral disc degeneration". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1872 (4) 119933. doi:10.1016/j.bbamcr.2025.119933. PMID 40096894.